– USA, MA – Axcella Health, a biotechnology company pioneering Designed Amino Acid Compositions as therapeutics across a range of important diseases, announced today that David R. Epstein has been elected as Chairman of its Board of Directors. Mr. Epstein is an Executive Partner at Flagship Pioneering.
“David is a tremendous and very timely addition to our Board of Directors, bringing over 25 years of drug development and commercialization experience from one of the world’s most successful pharmaceutical companies,” commented Dr. Noubar Afeyan, outgoing Chairman and Co-Founder of Axcella and CEO of Flagship Pioneering. “I look forward to working closely with David and the Axcella team on this truly pioneering platform with the potential to impact so many lives.”
“Axcella has made impressive progress advancing its DAAC candidates for the multifunctional modulation of essential biological pathways into the clinic and is ready to enter an accelerated growth phase,” commented David Epstein. “I look forward to being part of the effort in making this new class of innovative medicines available to patients.”
Robert Connelly, CEO of Axcella commented, “Our Axcellerator™ platform has produced a robust pipeline of DAAC candidates that address multiple indications, including liver, muscle and CNS diseases. David’s leadership will help us to advance our pipeline and prioritize the wealth of additional program opportunities the Axcellerator platform offers. I am very grateful for Noubar’s board leadership, and look forward to his continued contributions to Axcella, especially through the Board’s Science and Technology committee.”
About David R. Epstein
David R. Epstein is executive partner at Flagship Pioneering and executive chairman of Flagship-founded Rubius Therapeutics. Most recently, he served as chief executive officer of Novartis Pharmaceuticals, a division of Novartis AG, from 2010 to mid-2016. Previously, David started up and led Novartis’ Oncology and Molecular Diagnostic units. Under his leadership the company’s oncology business grew to the second largest in the world. David has more than 25 years of extensive global-scale drug development, deal making, commercialization and leadership experience. Over the course of his career he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto. He was recently named by FierceBiotech as one of the “25 most influential people in biopharma.”
About Axcella Health
Axcella has pioneered a new therapeutic class – Designed Amino Acid Compositions based on the recognition that complicated multifactorial diseases, where numerous cellular networks are involved, require multifunctional treatments. Our DAAC Therapeutics leverage the diversity and synergy of amino acid biology to restore health across a network of dysregulated pathways, and provide a differentiated tolerability profile for patients with complex disease. With our Axcellerator platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. This platform has already produced a rich pipeline of product candidates in programs that include liver, muscle, CNS and other target indications. The company was originated within Flagship’s VentureLabs innovation foundry and has been financed with $139 million to date.
For more information : http://www.axcellahealth.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.